CECOG Academy

www.cecog.org

 

CECOG Academy
W

CPIs in Cancer Treatment: Key Components of the Immune Defence, Immune Recognition, Surveillance / Evasion Mechanisms, IO Types, Combo Strategies to Avoid Resistance Development

By CECOG Academy FEATURING Walter Berger
By CECOG Academy FEATURING Walter Berger
0 views
April 13, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri
Videos
30:18
CECOG Academy

CPIs in Cancer Treatment: Key Components of the Immune Defence, Immu…

Feat. W. Berger
30:18
CECOG Academy

Rationale for Immune CPIs in Cancer Treatment: Key Concepts of the I…

Feat. W. Berger
20:56
CECOG Academy

Skeletal Health in Breast Cancer: Brief Comparison of BTAs in Advanc…

Feat. P. Dubsky
36:33
CECOG Academy

Neoadjuvant Treatment of NSCLC With Immune CPIs: Biological Understa…

Feat. C. Zielinski
05:03
CECOG Academy

Immune CPIs in ES-SCLC: How Effective Are Durvalumab, Atezolizumab &…

Feat. W. Kostler
06:52
CECOG Academy

Immune CPIs in NSCLC: Durvalumab After cCRT for Stage III, 2L Nivo, …

Feat. W. Kostler
18:57
CECOG Academy

1L Immune CPIs Efficacy Review for Advanced NSCLC: Single Agent IO, …

Feat. W. Kostler
19:19
CECOG Academy

Skeletal Health in Lung Cancer: Prevalence of Bone Mets, Prevalence …

Feat. J. Spasic
28:04
CECOG Academy

Immune CPIs as Mono and Combination Therapy for RCC: New 1L Strategi…

Feat. M. Schmidinger
25:07
CECOG Academy

Skeletal Health in Prostate Cancer: What Is the Impact of Long-Term …

Feat. D. Santini